Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: menon singh l. Breast Cancer Res Treat. 2021 Oct;189(3):689-699. doi: 10.1007/s10549-021-06334-0. Epub 2021 Aug 19. Breast Cancer Res Treat. 2021. PMID: 34414532 Free PMC article. Clinical Trial.
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Campone M, De Laurentiis M, Zamagni C, Kudryavcev I, Agterof M, Brown-Glaberman U, Palácová M, Chatterjee S, Menon-Singh L, Wu J, Martín M. Campone M, et al. Among authors: menon singh l. Breast Cancer Res Treat. 2022 May;193(1):95-103. doi: 10.1007/s10549-022-06543-1. Epub 2022 Feb 25. Breast Cancer Res Treat. 2022. PMID: 35212906 Clinical Trial.
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Cottu P, Ring A, Abdel-Razeq H, Marchetti P, Cardoso F, Salvador Bofill J, Martín M, Menon-Singh L, Wu J, De Laurentiis M. Cottu P, et al. Among authors: menon singh l. Breast. 2022 Apr;62:75-83. doi: 10.1016/j.breast.2022.01.016. Epub 2022 Jan 31. Breast. 2022. PMID: 35131646 Free PMC article. Clinical Trial.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: menon singh l. Breast Cancer Res Treat. 2022 Jan;191(1):223-224. doi: 10.1007/s10549-021-06374-6. Breast Cancer Res Treat. 2022. PMID: 34625861 Free PMC article. No abstract available.